| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hsien-Yuan Lane, Shih-Kuan Hsu, Yi-Ching Liu, Yue-Cune Chang, Chiung-Hsien Huang, Wen-Ho Chan. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643094. |
dopamine d3 receptor ser9gly polymorphism and risperidone response. |
2005-04-08 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Shih-Kuan Hsu, Yi-Ching Liu, Yue-Cune Chang, Chiung-Hsien Huang, Wen-Ho Chan. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643094. |
risperidone is a potent dopamine d3 antagonist and agonism at d3 sites induces behavioral suppression in rodents. |
2005-04-08 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Shih-Kuan Hsu, Yi-Ching Liu, Yue-Cune Chang, Chiung-Hsien Huang, Wen-Ho Chan. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643094. |
this study aimed to explore the influence of the ser9gly polymorphism of the dopamine d3 receptor (drd3) gene on response to risperidone after controlling for nongenetic factors. |
2005-04-08 |
2023-08-12 |
Not clear |
| . Case histories in drug discovery and design. Drug news & perspectives. vol 11. issue 1. 2005-03-30. PMID:15616642. |
the evolution of a new drug treatment for schizophrenia commenced with the observation that chlorpromazine possessed "neuroleptic" activity and progressed through studies with various dopamine and serotonin antagonists to ultimately lead to the discovery of risperidone. |
2005-03-30 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yue-Cune Chang, Chung-Ta Lu, Chiung-Hsien Huang, Wen-Ho Chan. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. The international journal of neuropsychopharmacology. vol 7. issue 4. 2005-02-24. PMID:15140279. |
effects of dopamine d2 receptor ser311cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. |
2005-02-24 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yue-Cune Chang, Chung-Ta Lu, Chiung-Hsien Huang, Wen-Ho Chan. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. The international journal of neuropsychopharmacology. vol 7. issue 4. 2005-02-24. PMID:15140279. |
the present study investigated the effect of the ser311cys polymorphism in the dopamine d2 receptor (drd2) gene on risperidone treatment response. |
2005-02-24 |
2023-08-12 |
Not clear |
| W G Frankle, R Gil, E Hackett, O Mawlawi, Y Zea-Ponce, Z Zhu, L D Kochan, C Cangiano, M Slifstein, J M Gorman, M Laruelle, A Abi-Dargha. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology. vol 175. issue 4. 2005-01-26. PMID:15083259. |
occupancy of dopamine d2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. |
2005-01-26 |
2023-08-12 |
Not clear |
| Gabriele Mas. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS drugs. vol 18. issue 14. 2004-12-29. PMID:15584771. |
pharmacological, efficacy and safety data on drugs acting on serotonin (serotonergic agents such as clomipramine, fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine), on both serotonin and norepinephrine (venlafaxine and mirtazapine), dopamine (dopamine-blocking antipsychotics such as haloperidol and pimozide), and on both serotonin and dopamine (atypical antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone) are presented. |
2004-12-29 |
2023-08-12 |
Not clear |
| Gerald A Maguire, Benjamin P Yu, David L Franklin, Glyndon D Rile. Alleviating stuttering with pharmacological interventions. Expert opinion on pharmacotherapy. vol 5. issue 7. 2004-11-02. PMID:15212606. |
novel dopamine antagonists such as risperidone and olanzapine, have recently been shown to improve the symptoms of stuttering providing a strong foundation for physicians to more effectively treat this disorder. |
2004-11-02 |
2023-08-12 |
Not clear |
| Stefan Leuch. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. The international journal of neuropsychopharmacology. vol 7 Suppl 1. 2004-09-14. PMID:14972080. |
the pharmacological profiles of the atypical antipsychotics, clozapine, olanzapine, quetiapine and risperidone, all show a combined serotonin (5-ht2) and dopamine type-2 (d2) receptor antagonism. |
2004-09-14 |
2023-08-12 |
Not clear |
| Kenichi Meguro, Mitsue Meguro, Yasuhiro Tanaka, Kyoko Akanuma, Keiichiro Yamaguchi, Masatoshi Ito. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. Journal of geriatric psychiatry and neurology. vol 17. issue 2. 2004-07-29. PMID:15157345. |
the binding potentials of dopamine d2 receptor for preadministration and postadministration of risperidone were assessed using positron emission tomography (pet) for 1 case. |
2004-07-29 |
2023-08-12 |
Not clear |
| György Szekeres, Szabolcs Kéri, Anna Juhász, Agnes Rimanóczy, István Szendi, Csongor Czimmer, Zoltán Jank. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 124B. issue 1. 2004-07-28. PMID:14681904. |
in this study, we investigated the relationship of the ser9gly (s/g) polymorphism of the dopamine d3 receptor (drd3) and the variable number of tandem repeats (vntr) polymorphism of the dopamine transporter (dat) with therapeutic response to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) and cognitive functions. |
2004-07-28 |
2023-08-12 |
Not clear |
| Hans Pihan, Klemens Gutbrod, Ulrike Baas, Armin Schnide. Dopamine inhibition and the adaptation of behavior to ongoing reality. Neuroreport. vol 15. issue 4. 2004-07-13. PMID:15094481. |
we present a patient who regained the ability to adapt thought and behavior to ongoing reality when treated with risperidone, a dopamine antagonist. |
2004-07-13 |
2023-08-12 |
Not clear |
| Tal Weizman, Chaim G Pick, Maria M Backer, Tova Rigai, Miki Bloch, Shaul Schreibe. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. European journal of pharmacology. vol 478. issue 2-3. 2004-06-17. PMID:14575800. |
based on previous studies with risperidone, clozapine and olanzapine we tend to attribute this global interaction with the opioid system to amisulpride's action at the dopamine d2 receptor sites. |
2004-06-17 |
2023-08-12 |
mouse |
| Maria A Aguilar, Jose Miñarro, Vicente M Simó. Morphine potentiates the impairing effects of neuroleptics on two-way active conditioned avoidance response in male mice. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 2. 2004-05-28. PMID:14751417. |
the effects of morphine (12.6 mg/kg), haloperidol (0.075 mg/kg), sulpiride (20 mg/kg) and risperidone (0.1 mg/kg) alone as well as morphine combined with these dopamine (da) antagonists on the acquisition and performance of the car were explored in mice. |
2004-05-28 |
2023-08-12 |
mouse |
| David Mamo, Gary Remington, Jose Nobrega, Doug Hussey, Raman Chirakal, Alan A Wilson, Glen Baker, Sylvain Houle, Shitij Kapu. Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. Synapse (New York, N.Y.). vol 52. issue 2. 2004-05-21. PMID:15034921. |
in rats, we studied the effect of a single subcutaneous injection of haloperidol and risperidone on dopamine synthesis using 6-[18f]-l-m-tyrosine. |
2004-05-21 |
2023-08-12 |
human |
| David Mamo, Gary Remington, Jose Nobrega, Doug Hussey, Raman Chirakal, Alan A Wilson, Glen Baker, Sylvain Houle, Shitij Kapu. Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. Synapse (New York, N.Y.). vol 52. issue 2. 2004-05-21. PMID:15034921. |
in our human study, six healthy volunteers underwent two 6-[18f]-l-m-tyrosine pet scans, before and after 3 mg risperidone to measure the rate of accumulation of radioactivity in the striatum as an index of dopamine synthesis. |
2004-05-21 |
2023-08-12 |
human |
| Akihiro Takano, Tetsuya Suhara, Yoko Ikoma, Fumihiko Yasuno, Jun Maeda, Tetsuya Ichimiya, Yasuhiko Sudo, Makoto Inoue, Yoshiro Okub. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. The international journal of neuropsychopharmacology. vol 7. issue 1. 2004-05-07. PMID:14764214. |
dopamine d2 receptor occupancies and plasma concentrations of risperidone were measured in five patients with schizophrenia using positron emission tomography with [11c]flb 457. |
2004-05-07 |
2023-08-12 |
human |
| Akihiro Takano, Tetsuya Suhara, Yoko Ikoma, Fumihiko Yasuno, Jun Maeda, Tetsuya Ichimiya, Yasuhiko Sudo, Makoto Inoue, Yoshiro Okub. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. The international journal of neuropsychopharmacology. vol 7. issue 1. 2004-05-07. PMID:14764214. |
mean half-life of dopamine d2 receptor occupancy of risperidone was 80.2 h while that of the plasma concentration was 17.8 h. dopamine d2 receptor occupancy estimated from plasma pharmacokinetics and in-vivo ed50 was within 1 s.d. |
2004-05-07 |
2023-08-12 |
human |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. |
2004-04-23 |
2023-08-12 |
mouse |